Comparison of basal-bolus and premixed insulin regimens in hospitalized patients with type 2 diabetes

Diabetes Care

Volumn 38, Issue 12, 2015, Pages 2211-2216

  Bellido, Virginia ^a   Suarez, Lorena ^a   Rodriguez, Maria Galiana ^a   Sanchez, Cecilia ^a   Dieguez, Marta ^b   Riestra, Maria ^b   Casal, Florentino ^b   Delgado, Elias ^a   Menendez, Edelmiro ^a   Umpierrez, Guillermo E ^c  

^a HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^b HOSPITAL DE CABUEÑES   (Spain)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN DERIVATIVE; INSULIN GLARGINE; INSULIN GLULISINE; ISOPHANE INSULIN PLUS PIG INSULIN; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; DRUG COMBINATION; GLUCOSE BLOOD LEVEL; HUMAN INSULIN; INSULIN; ISOPHANE INSULIN;

AGED; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; HYPOGLYCEMIA; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NUTRITIONAL SUPPORT; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; ANALOGS AND DERIVATIVES; ANALYSIS; CHEMICALLY INDUCED; COMPARATIVE STUDY; DIABETES MELLITUS, TYPE 2; DRUG COMBINATION; MIDDLE AGED;

AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG COMBINATIONS; FEMALE; HOSPITALIZATION; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN GLARGINE; INSULIN, ISOPHANE; INSULIN, REGULAR, HUMAN; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 84962449306     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc15-0160     Document Type: Article

References (30)

1. Umpierrez GE, Isaacs SD, Bazargan N, You X, Thaler LM, Kitabchi AE. Hyperglycemia: An independent marker of in-hospital mortality in patients with undiagnosed diabetes. J Clin Endocrinol Metab 2002;87:978-982.
2. Kosiborod M, Inzucchi SE, Spertus JA, et al. Elevated admission glucose and mortality in elderly patients hospitalized with heart failure. Circulation 2009;119:1899-1907.
3. Falciglia M, Freyberg RW, Almenoff PL, D'Alessio DA, Render ML. Hyperglycemiarelated mortality in critically ill patients varies with admission diagnosis. Crit Care Med 2009; 37:3001-3009.
4. Kotagal M, Symons RG, Hirsch IB, et al.; SCOAP-CERTAIN Collaborative. Perioperative hyperglycemia and risk of adverse events among patients with and without diabetes. Ann Surg 2015;261:97-103.
5. Umpierrez GE, Smiley D, Jacobs S, et al. Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes undergoing general surgery (RABBIT 2 surgery). Diabetes Care 2011;34:256-261.
6. Murad MH, Coburn JA, Coto-Yglesias F, et al. Glycemic control in non-critically ill hospitalized patients: A systematic review and meta-analysis. J Clin Endocrinol Metab 2012;97:49-58.
7. Schroeder JE, Liebergall M, Raz I, et al. Benefits of a simple glycaemic protocol in an orthopaedic surgery ward: A randomized prospective study. Diabetes Metab Res Rev 2012;28:71-75.
8. Munoz C, Villanueva G, Fogg L, et al. Impact of a subcutaneous insulin protocol in the emergency department: Rush Emergency Department Hyperglycemia Intervention (REDHI). J Emerg Med 2011;40:493-498.
9. Umpierrez GE, Hellman R, Korytkowski MT, et al.; Endocrine Society. Management of hyperglycemia in hospitalized patients in non-critical care setting: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2012;97: 16-38.
10. Moghissi ES, Korytkowski MT, DiNardo M, et al.; American Association of Clinical Endocrinologists; American Diabetes Association. American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Diabetes Care 2009;32:1119-1131.
11. Umpierrez GE, Smiley D, Zisman A, et al. Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes (RABBIT 2 trial). Diabetes Care 2007;30:2181-2186.
12. Ṕerez A. Glycemic control at hospital: Why does it not improve? Endocrinol Nutr 2012;59: 153-154.
13. Cook CB, Castro JC, Schmidt RE, et al. Diabetes care in hospitalized noncritically ill patients: more evidence for clinical inertia and negative therapeutic momentum. J Hosp Med 2007;2:203-211.
14. Kalra S, Balhara YP, Sahay BK, Ganapathy B, Das AK. Why is premixed insulin the preferred insulin? Novel answers to a decade-old question. J Assoc Physicians India 2013;61(Suppl.):9-11.
15. Rathmann W, Haastert B, Riebel P, et al. Prescription of insulin glargine in primary care practices in Germany. Exp Clin Endocrinol Diabetes 2007;115:252-256.
16. Charbonnel B, Balarac N, Cazeneuve B, Augendre-Ferrante B, Le Thaï F, Drouin P; Schema survey. Which are the insulin treatment regimens used in France? The "Schema survey". Diabetes Metab 2001;27:591-597.
17. Miser WF, Arakaki R, Jiang H, Scism-Bacon J, Anderson PW, Fahrbach JL. Randomized, openlabel, parallel-group evaluations of basal-bolus therapy versus insulin lispro premixed therapy in patients with type 2 diabetes mellitus failing to achieve control with starter insulin treatment and continuing oral antihyperglycemic drugs: A noninferiority intensification substudy of the DURABLE trial. Clin Ther 2010;32:896-908.
18. Schiel R, Müller UA, Rauchfub J, Sprott H, Müller R. Blood-glucose self-monitoring in insulin treated type 2 diabetes mellitus a cross-sectional study with an intervention group. Diabetes Metab 1999;25:334-340.
19. Eliasson B, Ekström N, Bruce Wirta S, Odén A, Fard MP, Svensson AM. Metabolic effects of Basal or premixed insulin treatment in 5077 insulin-näive type 2 diabetes patients: Registrybased observational study in clinical practice. Diabetes Ther 2014;5:243-254.
20. Ilag LL, Kerr L, Malone JK, Tan MH. Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: An evidence-based comparison. Clin Ther 2007;29:1254-1270.
21. Garber AJ, Ligthelm R, Christiansen JS, Liebl A. Premixed insulin treatment for type 2 diabetes: Analogue or human? Diabetes Obes Metab 2007; 9:630-639.
22. Hsia E, Seggelke SA, Gibbs J, Rasouli N, Draznin B. Comparison of 70/30 biphasic insulin with glargine/lispro regimen in non-critically ill diabetic patients on continuous enteral nutrition therapy. Nutr Clin Pract 2011;26:714-717.
23. Egi M, Bellomo R, Stachowski E, French CJ, Hart G. Variability of blood glucose concentration and short-term mortality in critically ill patients. Anesthesiology 2006;105:244-252.
24. Krinsley JS. Glycemic variability: A strong independent predictor of mortality in critically ill patients. Crit Care Med 2008;36:3008-3013.
25. Service FJ, Molnar GD, Rosevear JW, Ackerman E, Gatewood LC, Taylor WF .Mean amplitude of glycemic excursions, a measure of diabetic instability. Diabetes 1970;19:644-655.
26. Meynaar IA, Eslami S, Abu-Hanna A, van der Voort P, de Lange DW, de Keizer N. Blood glucose amplitude variability as predictor for mortality in surgical and medical intensive care unit patients: A multicenter cohort study. J Crit Care 2012;27:119-124.
27. Umpierrez GE, Smiley D, Hermayer K, et al. Randomized study comparing a basal-bolus with a basal plus correction insulin regimen for the hospital management of medical and surgical patients with type 2 diabetes: Basal plus trial. Diabetes Care 2013;36:2169-2174.
28. Kagansky N, Levy S, Rimon E, et al. Hypoglycemia as a predictor of mortality in hospitalized elderly patients. Arch Intern Med 2003;163: 1825-1829.
29. Stagnaro-Green A, Barton MK, Linekin PL, Corkery E, deBeer K, Roman SH. Mortality in hospitalized patients with hypoglycemia and severe hyperglycemia. Mt Sinai J Med 1995;62:422-426.
30. Turchin A, Matheny ME, Shubina M, Scanlon JV, Greenwood B, Pendergrass ML. Hypoglycemia and clinical outcomes in patients with diabetes hospitalized in the general ward. Diabetes Care 2009;32:1153-1157.